Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
(This code is effective for cases diagnosed 2021 and later. For cases diagnosed prior to 2021 see code: 9861/3.)
Patients often present with anemia and thrombocytopenia, and often have higher white blood cell and platelet counts than seen with other AML types. Cases may show extramedullary involvement, the most frequently affected sites are gingiva, lymph nodes, and skin.
Patients often present with anemia and thrombocytopenia, and often have higher white blood cell and platelet counts than seen with other AML types. Cases may show extramedullary involvement, the most frequently affected sites are gingiva, lymph nodes, and skin.
Diagnostic Confirmation
This AML is part of the "AML with recurrent genetic abnormalities" group. Since this AML is diagnosed based on genetics, diagnostic confirmation will always be 3.
Grade
Not Applicable
Module Rule
None
Definition
Acute myeloid leukemia (AML) with mutated NPM1 carries mutations that usually involve exon 12 of NPM1. Aberrant cytoplasmic expression of NPM1 is a surrogate marker of such mutations. This AML type frequently has myelomonocytic or monocytic features and typically presents de novo in adults with a normal karotype.
Definitive Diagnostic Methods
Genetic testing
Immunophenotyping
Genetics Data
Immunophenotyping
CD13+ (expression/positive)
CD14+ (expression/positive)
CD33+ (expression/positive)
CD34- (no expression/negative) (but can be positive)
CD36+ (expression/positive)
CD64+ (expression/positive)
CD110+ (expression/positive)
CD123+ (expression/positive)
HLA-DR- (no expression/negative)
KIT (CD117)+ (expression/positive)
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Transformations to
None
Transformations from
Same Primaries
Corresponding ICD-9 Codes
205.0 Acute myeloid leukemia
Corresponding ICD-10 Codes
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C92.0 Acute myeloblastic leukemia (effective October 01, 2015)
Signs and Symptoms
Diagnostic Exams
CT (CAT) scan
Cytogenetic analysis
Genetic testing
Immunophenotyping
Peripheral blood smear
Physical exam and history
Reverse transcription-polymerase chain reaction test (RT-PCR)
Progression and Transformation
None
Epidemiology and Mortality
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 141-142
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 141-142
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq